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Abstract
Herbal medicines have been widely used for the past millennia. Traditional Chinese medicine (TCM) is a major
modality in Chinese medical care and has garnered global attention owing to its pharmacological effects and multitargeted actions. The increased incidence of sequential or concurrent use of herbs and drugs in patients forces us to
consider herbedrug interactions (HDIs) in this modern era. One of the main causes of HDIs is modulation of drug
metabolism, in which cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT), and transporters play primary roles.
In this review, we focus on in vivo studies of HDIs, particularly in the treatment of cardiovascular disease (CVD), which
is currently the leading cause of disease-related mortality worldwide. A total of 55 HDIs are summarized, and their
potential underlying mechanisms are examined. The pharmacokinetic (PK) and pharmacodynamic (PD) effects of three
single herbs (Danshen, Ginseng, and Ginkgo) and four compound prescriptions (Shenmai injection, Shengmai-San,
Shu-Jing-Hwo-Shiee-Tang, and Wu-Chu-Yu-Tang) are discussed. Due to the complex compositions and PK/PD proﬁles
of TCMs, the determinants of signiﬁcant HDIs have been listed to further deﬁne the pros and cons of HDIs in medical
care.
Keywords: Cytochrome P450, Herb-drug interaction, Traditional Chinese medicine, Transporter,
UDP-Glucuronosyltransferase

1. Introduction

H

erbal products used as dietary supplements or
complementary medicines have greatly
expanded in the past few decades to meet health
needs and for disease treatments [1]. Both the economic marketing and clinical applications of herbal
medicines have increased worldwide [1,2]. In the US

alone, the number of individuals using herbal
medicines or dietary supplements increased from
12% in 1997 to 35% in 2015, representing 6.4 billion
US dollars of marketing in 2015 [1,2]. Approximately
14% of these medicinal herbs are derived from plant
species used in traditional Chinese medicine (TCM)
[3]. The history of TCM applications in disease
therapies has been recorded for millennia. Since
nearly 20% of the world's population uses TCM as
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the main or auxiliary treatment for diseases ranging
from acute to chronic and mild to severe [4], the
safety of TCM use should be considered [3,5],
particularly with cardiovascular diseases (CVDs)
exhibiting high mortality rates.
Over the past 20 years, heart disease has remained
the leading cause of death worldwide. In 2019, 17.9
million deaths due to CVDs represented 32% of
deaths from all causes [6]. In addition to conventional Western drugs, 80% of patients with hypertension in Taiwan have used TCMs at least once
during the course of the disease [7]. This situation is
particularly likely to occur in patients who are
elderly and those with chronic diseases such as
CVD [8], cancer, and diabetes, because these patients generally require long-term treatment with
synthetic drugs, and they are highly likely and
willing to use herbal medicines for health
improvement [9].
The term “herb-drug interactions” (HDIs) has
appeared in the literature since the 1980s [10].
Possibly because “natural plants” are believed to be
safe, the interactions between herbal medicines and
prescription drugs are under-reported [11]. It was
not until 2000, when Dr. Fugh-Berman's highly cited
report was published, that HDI discussions became
more widespread [12]. Some published reports
subsequently evaluated the curative effects of the
combined use of herbal and prescription drugs, and
many have investigated the mechanisms involved in
HDIs. One such mechanism is herb-elicited alterations of drug metabolism, in which cytochrome
P450s
(CYPs),
UDP-glucuronosyltransferases
(UGTs), and membrane transporters are the main
contributors [13e16]. Research on HDIs driven by
CYP regulation is the most extensive and in-depth
[17], while the understanding of HDIs involving
UGTs and transporters has only improved in recent
years [18,19]. The importance of UGTs and transporters in HDIs has gradually increased, and some
of their effects are discussed in this review.
The present report reviews the CYP/UGT/transporter-mediated interactions between TCMs and
drugs that are highly prescribed for ameliorating
CVD-related symptoms. The drugs discussed in this
report include anticoagulants, calcium channel
blockers, hypolipidemics, and therapeutic agents for
bradycardia and migraine. The potential mechanisms underlying the modulation of CYPs, UGTs,
and transporters are summarized. In addition, any
inconsistent data on HDIs that may result from
inter-study differences are presented and discussed
in this review. Finally, a scheme of inﬂuencing factors is provided for further studies to establish

Abbreviations
AUC
CAR
CVD
CYP
HDI
HLMs
OATP
PD
P-gp
PK
PXR
SJHST
SMI
SMS
TCM
UGT
WCYT

area under the plasma concentration versus time
curve
constitutive androstane receptor
cardiovascular disease
cytochrome P450
herbedrug interaction
human liver microsomes
organic anion transporting polypeptide
pharmacodynamic
P-glycoprotein
pharmacokinetic
pregnane X receptor
Shu-Jing-Hwo-Shiee-Tang
Shenmai injection
Shengmai San
traditional Chinese medicine
UDP-glucuronosyltransferase
Wu-Chu-Yu-Tang

appropriate herbal use when herbs and drugs
interact.

2. Metabolic process-mediated herb-drug
interactions (HDIs)
Pharmacokinetic (PK) and pharmacodynamic
(PD) interactions are the primary mechanisms underlying HDIs. Modulation of CYPs, UGTs, and
transporters appears to be the key pathway in PK
interactions. Here, we brieﬂy introduce these
membrane-bound enzymes/transporters and present some mechanisms that dominate HDIs.
2.1. Background of CYPs, UGTs, and transporters
2.1.1. Cytochrome P450 (CYP)
In a 2015 report on the oxidations of marketed
drugs and those under development, CYPs participated in ~96% of drug oxidations [16]. In addition to
drugs, CYPs catalyze ~94% of the oxidation of
physiologically occurring substances and natural
products. Drug-metabolizing CYP isoforms are
mainly localized in cellular endoplasmic reticulum,
which is the microsomal fraction after differential
centrifugation of the tissue homogenate. Drug
oxidation catalyzed by the microsomal CYPdependent monooxygenase system requires the
transfer of two electrons with the aid of a ﬂavoprotein NADPH-CYP reductase (CPR) (Fig. 1). The hemoprotein cytochrome b5 assists in the second
electron transfer in the catalytic cycle of CYP [20]. In
some instances, the presence of cytochrome b5
stimulates the oxidation velocity in a reconstituted
human CYP-dependent monooxygenase system
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Fig. 1. The CYP- and UGT-catalyzed metabolic reactions, using the hydroxylation and naloxone glucuronidation as the representative, respectively.
The hydroxylation and glucuronidation were separated by a dash line. CYP (represented by the proposed structure of CYP3A4 based on Protein Data
Bank (PDB) ID: 1W0E) and UGT (represented by the proposed structure of UGT2B7) are anchored in the endoplasmic reticulum (ER) membrane with
the active sites facing to the cytosolic and lumen sites, respectively. The principal features of the consensus mechanism of CYP oxidation and UGT
conjugation are as demonstrated in the topologic diagrams. On the left, the representative hydroxylation catalyzed by CYP-dependent monooxygenase
is divided into six steps (①e⑥). They are ① substrate binding; ② electron transfer from NADPH via CPR (the proposed structure based on PDB ID:
5FA6) to reduce ferric heme; ③ oxygen insertion; ④ a second electron transfer via CPR and cytochrome b5 (the proposed structure based on PDB ID:
2I96) ⑤ dioxygen bond splitting and the formation of a reactive iron-oxo intermediate and release one molecule of water; ⑥ oxygen-atom transfer to
the bound substrate and product dissociation [31]. On the right is the process of naloxone glucuronidation, which is divided into four steps (❶e❹). ❶
a cofactor UDP-glucuronic acid (UDPGA) is recognized by the signature motif of UGT in highly conserved C-terminal domain (the proposed structure
based on PDB ID: 2O6L); ❷ aglycone substrate is attached to least conserved N-terminal domain, and UGT catalyze substrate when both UDPGA
and substrate are bound at the active site; ❸ a-D-glucuronic acid is substituted to substrate by SN2 nucleophilic reaction to form a hydrophilic b-Dglucuronide; ❹ the conjugated metabolite is pumped out from inner endoplasmic reticulum via OATER [32].

[20,21] and in mice expressing human CYPs [22].
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A
are the main human CYP isoforms known to be
important for the oxidations of cardiovascular drugs
(Table 1) [23,24]. Among human tissues, the liver
has the highest total CYP content and is primarily
responsible for the systemic metabolism of drugs
and natural products. However, intestinal ﬁrst-pass
metabolism is a determining factor in the restricted
bioavailability of drugs, such as nifedipine and
felodipine [24].
2.1.2. UDP-glucuronosyltransferase (UGT)
Glucuronidation catalyzed by UGTs is the most
prevalent metabolic process in phase II reactions,
and approximately 40e70% of clinical drugs and
herbal medicines are metabolized by UGTs [18].
UGTs are mainly distributed in the liver and
gastrointestinal tract [25] and participate in the
glucuronidation of endogenous substances, such as

steroids and bilirubin, as well as xenobiotics,
including medicinal herbal ingredients and drugs
[18,26]. The gastrointestinal tract is the main area
exposed to extraneous substances after ingestion. As
most TCMs are administered to patients orally,
there is a considerable opportunity for TCMs to
regulate intestinal UGTs under high exposure concentrations. Previous reports revealed that natural
products, such as schisantherin A and schisandrin
B, were present at higher levels in the intestine than
in the liver and altered nifedipine bioavailability
after oral administration [27,28]. In addition to
changes in the liver with abundant UGT levels, the
potential effects of natural products on intestinal
UGT cannot be ignored in HDI assessments.
UGTs are mainly anchored to the endoplasmic
reticulum on the luminal side and are partly localized to the nuclear envelope (Fig. 1). Unlike CYPs,
conjugation reactions of UGTs occur in the lumen of
the endoplasmic reticulum rather than on the
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Table 1. CVD drug substrates of human main hepatic CYPs and the nuclear receptor/factor involved in the regulation of CYP expression.
Isoform

Drug substrate

Nuclear receptor/factor

SNP of nuclear receptor

CYP1A2

Caffeine
Propranolol
Theophylline
Ticlopidine
Azilsartan
Fluvastatin
Losartan
Pitavastatin
Rosuvastatin
Warfarin
Cilostazol
Clopidogrel Phenytoin Ticlopidine
Mexiletine Metoprolol
Propranolol
Ticlopidine
Amlodipine
Apixaban
Atorvastatin
Cilostazol
Cyclosporine A Felodipine
Losartan
Lovastatin
Nifedipine
Rivaroxaban
Simvastatin
Ticlopidine

AhR

Yes [47,48]

CAR, PXR

Yes [49,50]

CAR, PXR

Yes [49,50]

HNF-4a

Yes [49e51]

PXR

Yes [49,50]

CYP2C9

CYP2C19
CYP2D6

CYP3A4

AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; HNF-4a, hepatocyte nuclear factor 4a; PXR, pregnane X receptor; SNP: single nucleotide polymorphism.

cytosolic side. Therefore, it is believed that glucuronidation exhibits a lag time, and the substrate must
wait to pass through the cell membrane and enter
the endoplasmic reticulum before conjugation can
proceed [29]. Among human UGTs, UGT1 and
UGT2 are the main families, containing 9 and 10
members, respectively [30]. Compared to UGT1 and
UGT2, UGT3 and UGT8 were discovered later and
are rarely involved in drug metabolism.
2.1.3. Transporters
Transporter-based interactions are sometimes
referred to as phase III reactions, which are
responsible for the absorption, distribution, and
elimination of consumed substances, including
drugs and herbal ingredients [33,34]. In addition to
the well-known phase I and II metabolizing enzymes, transporters have been recognized to play an
essential role in HDIs, resulting in signiﬁcant clinical impacts [35,36]. Transporters are clusters of
membrane-bound proteins that mediate the movement of endogenous and exogenous substances
across biological membranes. They are broadly
distributed in the body (e.g., intestines, liver, kidneys, brain, and placenta) and are divided into two
superfamilies: ATP-binding cassette (ABC) and solute carrier (SLC) transporters. The ABC

transporters, such as P-glycoprotein (P-gp), breast
cancer resistance protein, and multidrug resistanceassociated protein 2, direct substances outward from
the inside to the outside of the cell using the energy
derived from ATP hydrolysis [37]. In contrast, SLC
proteins (e.g., organic anion transporter, organic
cation transporter, and organic anion transporting
polypeptide (OATP)) transport substrates in the
reverse direction [35,38]. Generally, in the intestines
and liver, ABC transporters are localized on the
apical/canalicular side of the epithelium to minimize xenobiotic threats by pumping toxic substances out. Conversely, SLC transporters are
located on the basolateral/sinusoidal side and are
primarily responsible for substance uptake (Fig. 2).
2.2. Mechanisms of HDIs
2.2.1. Modulation of CYPs
Modulation of CYPs can reveal tissue speciﬁcity,
species differences, and individual differences
among people [23]. Increased CYP activity can be
attributed to multiple regulatory mechanisms
including nuclear receptor-triggered transcriptional
upregulation, post-transcriptional induction, and
decreased protein degradation. For example, St
John's wort (Hypericum perforatum) stimulated
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Fig. 2. Localization of transporters in enterocyte and hepatocyte and their direction of ﬂux on drugs. The membrane transporters involved in drug
intestinal absorption and hepatobiliary disposition can be divided into inﬂux (uptake) and efﬂux proteins. The amount of drug systemic exposure
mediated by the membrane pumps depend on the distribution and acting direction of the transporters on the cell apical/sinusoidal or basolateral/
canalicular side. CYP, cytochrome P450; BCRP, breast cancer resistance protein; BSEP, bile salt export pump; MRP, multidrug resistance associated
protein; NTCP, sodium taurocholate co-transporting polypeptide; OAT, organic anion transporter; OATP, organic anion transporting polypeptide;
OCT, organic cation transporter; P-gp, P-glycoprotein; UGT, UDP-glucuronosyltransferase.

CYP3A expression through pregnane X receptor
(PXR)-triggered transcriptional induction, and its
ingredient hyperforin was the main contributor to
this induction [39]. Reduced CYP activity could be
attributed to the decreased activities or expression
levels of CYP and/or its electron-transfer partners
(Fig. 1). Decreased activity is mostly attributed to
reversible inhibition through different types of
competitive inhibition [23,40]. Compared to reversible inhibition, time-dependent (mechanism-based)
CYP inhibitors cause a more potent inhibitory effect,
and the impaired function can only be restored
through de novo protein synthesis of CYP. Timedependent inhibitors cause suicidal inactivation
through CYP-mediated oxidization to generate an
active metabolite that irreversibly binds to CYP itself, leading to functional inactivation [41]. Irreversible inactivation and detection of a signiﬁcant

functional defect require time for drug oxidation
and the accumulation of inactivated CYP. Grapefruit
ingredients decreased intestinal, but not hepatic
CYP3A4 function, through time-dependent inhibition [42]. In healthy participants, ingestion of
grapefruit juice 2 h prior to oral administration of
the CYP3A4 substrate midazolam signiﬁcantly
increased the area under the plasma drug
concentrationetime curve (AUC) of midazolam [43].
Recovery of the AUC to the level before grapefruit
juice ingestion required 3 days.
Single nucleotide polymorphisms (SNPs) are one
of the factors that inﬂuence CYP induction and inhibition [44e50]. SNPs exist in both CYPs and nuclear receptors (Table 1), resulting in individual
differences not only in CYP function, but also in
CYP inducibility and susceptibility to inhibition.
SNPs represent one class of crucial factors that
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inﬂuence drug dosing regimens in patients with
CVD [44]. The genetic variants of CYPs and their
inﬂuence on changes in amino acid residues and
CYP function can be found on the PharmVar web
site (https://www.pharmvar.org) [45,46].
2.2.2. Herb-mediated modulation of UGTs
Various natural products have been reported to
alter the expression or function of UGTs through
receptor activation-elicited induction [52] or functional suppression [18]. Flavonoids are a group of
phenolic antioxidants commonly found in various
herbal medicines (e.g., Ginkgo biloba) and have been
shown to act as UGT substrates or strongly inhibit
UGT activity [18]. The Japanese Kampo medicine
Hange-Shashin-To (TJ-14) contains baicalin, the
main ﬂavonoid in Scutellaria baicalensis, and potently
inhibits the glucuronidation of SN-38 (main active
metabolite of irinotecan) in human liver microsomes
(HLMs) [53]. b-Glucuronidase treatment enhanced
the UGT inhibitory effect of TJ-14. The conjugated
glucuronic acid of baicalin can be removed by intestinal glucuronidase to generate baicalein, which
potently inhibited UGT activity in a competitive
manner with an inhibition constant (Ki) of 8.7 mM.
The simultaneous use of other ﬂavonoid-rich herbal
medicines may produce HDIs with CVD drugs that
are also UGT substrates, such as aspirin, telmisartan, and coumarin derivatives [54e56]. Other
plant ingredients that regulate UGTs have also been
reported [18]. Since most HDI studies related to
UGTs have been conducted in vitro, further PK/PD
studies are urgently needed to evaluate the safety of
concurrent uses of herbal medicines and UGT drug
substrates.
2.2.3. Modulation of inﬂux and efﬂux transporters
In addition to CYP induction, the PXR and
constitutive androstane receptor (CAR) are wellknown transcription factors related to the

modulation of transporters [57]. CAR overlaps with
PXR in many aspects, such as being regulated by
herbal medicines and affecting gene expression of
drug-metabolizing enzymes and transporters
[58,59]. For example, hyperforin increased intestinal
P-gp activity, thereby reducing the plasma level of
the human immunodeﬁciency virus drug indinavir
by 57% [60]. The extensively studied ﬂavonoid
quercetin is present in many herbal medicines and
is rich in Ginkgo Folium. Rutin, the glycoside of
quercetin, induces OATP2B1 expression, leading to
a decrease in rosuvastatin uptake [61]. Due to its
dual inductive effects on CYP3A4 and P-gp, quercetin has been shown to elicit signiﬁcant HDIs
[62,63]. However, other conﬂicting reports have
indicated that quercetin elevates doxorubicin and
etoposide levels in rats by attenuating the activities
of CYP3A4 and P-gp [64,65]. The underlying reason
for this discrepancy remains unclear. It is worth
mentioning that another type of “enzyme-transporter” interplay may also exist in HDIs [66]. If
perpetrators (herbs) act as enzyme/transporter inhibitors and PXR inducers, the fate of the victim
drugs may depend on the relative potency of these
two opposing actions [66]. Schisandrae Fructus
(Wu-Wei-Zi), a common TCM used to treat CV
disorders, is a typical example of this phenomenon
[66].
Depending on the target proteins, affected sites,
and inﬂux/efﬂux directions, the modulation of
transporters may signiﬁcantly alter the PK proﬁles
of concurrently used drugs. The commonly used
Panax ginseng induces P-gp activity, which in turn
increases the bioavailability of fexofenadine (an
antihistamine) [67]. Glycyrrhiza showed potent
inhibitory effects against breast cancer resistance
proteins and P-gp, resulting in increased exposure
to co-administered drugs [68]. However, it should
be noted that contradictory HDIs between TCMs
and transporters are not uncommon in the

Table 2. The main active ingredients of three single herbs potentially regulate drug-metabolizing enzymes and transporters.
Danshen (Salvia miltiorrhiza) [83,84]

Ginseng (Panax ginseng) [95]

Ginkgo (Ginkgo biloba) [124,129]

Lipophilic diterpenoids:
Cryptotanshinone
Dihydrotanshinone
Tanshinone I
Tanshinone IIA
Hydrophilic depsides:
Danshensu (salvianic acid A)
Protocatechuic aldehyde
Rosmarinic acid
Salvianolic acid A
Salvianolic acid B

Ginsenosides
Ginsenoside Rg1
Ginsenoside Rc
Ginsenoside Rd
Ginsenoside Re
Ginsenoside Rb1
Ginsenoside Rb2
Flavonoids
Sterols
Polysaccharide
Compound K

Flavonoids
Quercetin
Kaempferol
Apigenin
Isorhamnetin
Terpene trilactones
Ginkgolide A
Ginkgolide B
Ginkgolide C
Ginkgolide J
Ginkgolide K
Ginkgolide M
Bilobalide

literature. For example, silymarin (milk thistle)
decreased systemic exposure (AUC0-48) of the P-gp
substrate metronidazole by 27.9% [69], whereas it
increased the AUC0-36 of another P-gp substrate,
talinolol, by 36.2% in participants [70]. Moreover,
Danshen ingredients, cryptotanshinone and dihydrotanshinone, reduced P-gp expression and
decreased the efﬂux ratio of digoxin in colon cancer
cells [71], whereas tanshinone IIA and cryptotanshinone induced the expression of P-gp mRNA in
cryopreserved human hepatocytes [72]. These contradictory results may be related to the complex and
cell-type speciﬁc actions of herbal ingredients.
Variations in the dosing regimens, enzyme-transporter interactions, and composition of herbal
medicines are also potential causes [73e75].
HDIs between herbal medicines and uptake
transporters are relatively rare compared with those
between herbal medicines and efﬂux transporters.
However, a growing body of evidence has shown
that many TCMs (e.g., Danshen, Huanglian, and
licorice) have signiﬁcant effects on the function of
uptake transporters [36]. The clinical impact of the
changes in cellular drug-uptake by these TCMs
cannot be ignored, particularly because they are
often included in compound formulas.

3. Potential HDIs between single TCMs and
prescribed CVD drugs
As mentioned above, driven by the culture of
Chinese medicine and dietary habits, the consumption of TCMs is prevalent in Asia, especially in
patients with chronic diseases such as CVD. The
active ingredients of three herbs are indicated in
Table 2, and the progress to date of the HDI-relevant in vivo studies of these herbs and the four
compound formulas described in section 4 are
summarized in Table 3. These herbs and formulas
are included because they have been reported to be
frequently used to ameliorate CVD-associated
symptoms and have the potential to interact with
CVD drugs by altering drug metabolism, as discussed in the following sub-sections.
3.1. Danshen (Salvia miltiorrhiza)
Danshen (Salviae miltiorrhizae Radix et Rhizoma),
the dried root and rhizome of S. miltiorrhiza, is a
Chinese herbal drug widely used to treat CVDs [76].
Danshen can react directly with CVD drug targets
relevant to antithrombotic effects, including
thrombin, activated coagulation factor X, and
cyclooxygenase 1 [77]. However, the clinical indications for Danshen are broad, including angina,
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coronary artery disease, hypertension, and many
other CV-derived symptoms [76]. In Taiwan,
Danshen was the most frequently prescribed herb
used in patients with hypertension from 2003 to
2009 (17.1%), with an average daily dose of 2.3 g
powdered decoction [7]. Danshen was also the most
commonly used herbal medicine in the prescriptions for ischemic heart disease [7,78]. Danshen
extract and Danshen-containing formula, such as
Danhong injection and compound Danshen dripping pill (Danshen, Sanqi, and Borneol), are often
used in combination with prescribed Western drugs
to treat CVD.
The underlying mechanisms of the interplay between Danshen and drugs have been studied for a
long time, and CYP-mediated interactions, although
controversial, have been identiﬁed as the major
causes of Danshen-induced interaction with CVD
drugs. As shown in Table 3, potentially through
CYP3A4 induction by either the hydrophilic ingredient (salvianolioc acid B) or the hydrophobic ingredients (cryptotanshinone and tanshinone IIA),
repeated treatments with Danshen capsule/tablet
decrease clopidogrel and atorvastatin exposures in
humans and rats, respectively [79,80]. However, by
using midazolam as a CYP3A marker substrate,
another preparation of Danshen extract caused the
opposite inﬂuence accompanied by a decreased
CYP3A protein level in rats [81]. A mouse study of
the aqueous decoction of Danshen and Gegen (the
dried root of Pueraria lobata) (DG, 7:3 w/w) showed
that 8-week co-treatment with atorvastatin and DG
resulted in stronger hypolipidemic effects than
treatment with atorvastatin or DG alone, potentially
owing to CYP3A suppression [82]. One explanation
for these discrepancies may be the differential
herbal composition and CYP/transporter-modulatory effects of the hydrophilic and hydrophobic
constitutes extracted from Danshen [83]. At least
nine primary pharmacologically active ingredients
found in Danshen (Table 2) play signiﬁcant roles in
altering CV functions [83,84]. It is believed that the
hydrophobic ingredients in Danshen, rather than
the water-extracted constituents, are much more
potent in interfering with the activities of CYP enzymes. However, the hydrophilic ingredients (e.g.
tanshinol and salvianolic acid B) may have some
effects on transporters (especially SLC members),
whose involvement can alter PK behaviors of CVD
drugs [83]. Another possible reason for these
controversial results is the difference between
enzyme inhibition after short-term treatment and
enzyme induction (mediated by PXR activation)
after long-term administration and the effects of
Danshen dosing frequency thereon [85]. Because of
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TCM

Interacted
CVD Drug

Study
design

Ingredient
mentioned

Danshen
tab, 100
mg/kg/d,
po, 7 days
Danshen
tab, 100
mg/kg, po,
single dose
Water extract
of Danshen and
Gegen (7:3,
w/w), 600 mg/kg/d,
po, 8 weeks

Possible
underlying mechanism
Phase I & II

Transporter

Salvianolic acid B

CYP3A ([)

NA

Salvianolic acid B

CYP3A ([)

NA

NA

CYP3A (Y)

NA

CYP2B1 (Y) NA
CYP2C6 (Y)
CYP2C11 (Y)

Danshen
Amlodipine
(Salvia
1 mg/kg, po,
miltiorrhiza) single dose

SD rats,
n¼6
in each group

Atorvastatin
1 mg/kg, po,
single dose

SD rats,
n ¼ 6 in each
group

Atorvastatin
8 or 16 mg/
kg/d, po,
8 weeks

C57BL/6 mice,
n ¼ 19e25 in
all groups

Azilsartan
2 mg/kg,
po, single dose

SD rats,
n ¼ 6 in
each group

DDP (Danshen,
Sanqi, Bingpian),
81, 405, 810
mg/kg/d, po, 7 days

Danshensu,
salvianolic acid
A and B,
protocatechuic
aldehyde and
rosmarinic acid

Clopidogrel
300 mg, po,
single dose

Human
healthy
subjects,
cross-over
n ¼ 20

Danshen cap,
4's (0.56 g/cap),
po, tid, 7 days
before drug coadministration

Cryptotanshinone and CYP3A4 ([)
tanshinone IIA

Clopidogrel
30 mg/kg, po,
single dose

SD rats,
n ¼ 4 in
study and
control groups

Danshen extract,
400 mg/kg, po,
single dose

Tanshinone I,
IIA, IIB,
dihydrotanshinone,
and cryptotanshinone

CYP3A (↔)

Signiﬁcant
Physiological
effect on PK
impact
of concurrent druga

Ref

Cmax (Y) 26.5%
AUCt (Y) 52.4%
t1/2 (Y) 25.1%
CL/F ([) 135.8%
Cmax (Y) 38.7%
AUCt (Y) 46.9%
t1/2 (Y) 30.3%
CL/F ([) 98.7%
NA

NA

[149]

NA

[80]

(1) DDP 81
mg/kg/d:
Cmax ([) 96.1%
AUCt ([) 77.9%
CL/F (Y) 72.2%
(2) DDP 405
mg/kg/d:
Cmax ([) 97.3%
AUCt ([) 88.8%
CL/F (Y) 72.2%
(3) DDP 810
mg/kg/d:
Cmax ([) 113.3%
AUCt ([) 103.0%
CL/F (Y) 77.8%
Induction of
(1) Clopidogrel:
P-gp may
Cmax (Y) 41.7%
also take part AUCt (Y) 50.3%
in the
CL/F ([) 96.5%
interactions
(2) Active thiol
metabolite:
Cmax (Y) 32.9%
AUCt (Y) 41.8%
CL/F ([) 73.7%
P-gp (↔)
Non-signiﬁcant
change

Signiﬁcant hypo- [82]
lipidemic effect:
Body weight (Y)
Liver weight (Y)
Liver fat (Y)
Adipose tissue (Y)
Lipid proﬁle (Y)
NA
[150]

IPA Y
[79]
Reduction of the
inhibitory effect of
platelet
aggregation

NA

[151]
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(dose, route,
duration)
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Table 3. The metabolism-mediated HDIs associated CVD in the in vivo animal and clinical studies.

Clopidogrel
31 mg/kg, po on
day 1 and 7.75
mg/kg for 13
days þ Aspirin
8.3 mg/kg,
po for 14 days
Losartan
10 mg/kg, po,
single dose

Danshen,
1.03 g/kg/d or
1.55 g/kg/d,
po, 2 weeks

Salvianolic acid

CYP2C11 (Y) NA

Non-signiﬁcant
change

No signiﬁcant
changes in PT

[152]

SD rats, n ¼ 6
in each group

Compound
Danshen tab
1's, po, single dose

Salvianolic acid
B (36.2 mg/kg)
and tanshitone
IIA (2.7 mg/kg)

Induction of Competition
CYP enzymes of
transportation
protein

NA

[153]

CYP1A2 (↔) NA
(Possibly due
to the low oral
BA of lipophilic components of
Danshen)
NA
NA

(1) Losartan:
AUCt (Y) 9.8%
Cmax (Y) 6.1%
t1/2 (Y) 13.3%
CL/F ([) 7.4%
(2) EXP3174:
No signiﬁcant
change
No signiﬁcant
change

NA

[154]

No signiﬁcant
change

No signiﬁcant
change in PT

[88]

No signiﬁcant
change, but the
peak
concentrations
of S-warfarin ([
15.8%) and
total warfarin
([ 13.7%)
signiﬁcantly
increased in
CYP4F2 C/C
patients
No signiﬁcant
effect on steadystate PK of
warfarin

No signiﬁcant
change in INR

[89]

Theophylline
100 mg, po,
single dose

Human healthy Danshen tab 4's,
subjects, cross- po, tid for 14
over n ¼ 12
days before
drug coadministration

Cryptotanshinone,
tanshinone I,
tanshinone IIA,
danshensu, and
salvianolic acid B

Warfarin
1.0 mg/kg, po

Wistar rats,
n ¼ 6 in
each group

Warfarin
3.41e3.39 mg, po

Human CVD
patients,
sequential
n ¼ 59

Compound DDP
(Danshen, Sanqi,
Bingpian), 50 mg/kg
or 250 mg/kg, po,
bid, 7 days
Compound DDP
(Danshen, Sanqi,
Bingpian), 10
grains, po,
tid, > 4 weeks

Tanshinol,
protocatechuic
aldehyde, rosmarinic
acid, salvianolic acid
A, B, and D
Danshensu,
protocatechuic
aldehyde, rosmarinic
acid, and salvianolic
acid A

Warfarin
2e6.5 mg, po,
25 days

Human, healthy
subjects,
sequential
n ¼ 23

T89 (Danshen,
Sanqi, Borneol),
225 mg, po, bid,
7 days

Tanshinone I,
tanshinone IIA,
cryptotanshinone, and
salvianolic acids

(1) Warfarin
1 mg/d, po, 5 days

Human, healthy Danshen-Gegen (7:3)
subjects, 5-ses- 750 mg, po, bid,
sion n ¼ 12e14 5 days

Danshensu,
protocatechuic
aldehyde, salvianolic

NA

NA

No effects on NA
CYP1A2, 2B6,
2C8, 2C9,
2C19, 2D6,
and 3A4/5
CYP2C9 (Y) NA

No signiﬁcant
change in INR,
the bleeding
risk possibly prevented by Sanqi
(1) 7-OH warfarin: (1) Warfarin:
AUCt (Y) 53.5%
plasma thrombomodulin (Y)
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SD rats, n ¼ 6
in each group

[155]

[156]
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Table 3. (continued )
Study
design

TCM
administration
(dose, route,
duration)

(2) Aspirin
100 mg/d, po, 5 days

Danshen
240 mg/kg/d or
480 mg/kg/d,
po, 5 days

(1) Warfarin
SD rats,
2 mg/kg, po,
n ¼ 6 in
each group
single dose
(2) Warfarin 0.2 mg/
kg/d, po, 8 days

(1) For single
dose warfarin:
DEAE, 50 or
200 mg/kg/d,
ip, single dose
or 3 days
(2) For multiple
dose warfarin:
DEAE, 2 g/kg, po,
bid, 4 days

(1) Amlodipine
10 mg/kg, po,
single dose
(2) Amlodipine 2 mg/
kg, iv, single dose
Cocktail probe:
Caffeine 200 mg,
losartan 50 mg,
dextromethorphan
30 mg, omeprazole
20 mg, midazolam
7.5 mg, and

RG from 0.5 to 2
g/kg/d, po,
2 weeks

SD rats,
n ¼ 5e9

Human
healthy

RG solution,
10 mL/d
(dried
subjects, cross- Ginseng 64%),
over n ¼ 14
po, qd, 2 weeks

Possible
underlying mechanism
Phase I & II

acid B,
cryptotanshinone,
tanshinone I and
tanshinone IIA
Danshensu,
salvianolic
acid B, and
protocatechuic
aldehyde
DEAE:
tanshinone
I, tanshinone
IIA, and
cryptotanshinone

Transporter

Signiﬁcant
Physiological
effect on PK
impact
of concurrent druga
(2) Aspirin:
AUCt ([) 242.2%

(2) Aspirin:
thromboxane B2
formation (Y)

No effects
NA
on CYP2C11,
2C6, 1A1, and
2B1

No signiﬁcant
change

No signiﬁcant
change

CYP1A1 (Y) NA
CYP2C6 (Y)
CYP2C11 (Y)

(1) Single
NA
DEAE 50 mg/kg:
AUC (Y) 21.4%
t½ (Y) 35.8%
CL/F ([) 27.5%
(2) Single DEAE
200 mg/kg:
Cmax (Y) 28.0%
(3) Multiple DEAE
50 mg/kg/d:
No signiﬁcant
change
(4) Multiple DEAE
200 mg/kg/d:
Cmax (Y) 27.3%
AUC4’-OH
warfarin (Y) 47.1%
AUC7-OH
warfarin (Y) 33.1%
(5) Multiple DEAE
2 g/kg:
Css ([) 23%
No signiﬁcant
NA
changes

Ginsenosides
Rg1, and Rb1

CYP3A4 (↔)

NA

Ginsenosides
Rb1, Rb2,
Rc, Re, F2, Rg1,
20(S)-Rg3, 20(R)-Rg3,
20(S)eRh1, 20(S)/20(R)Rh2, 20(R)-Rh1/Rd/F1,
compound K,

CYP1A2 (Y) P-gp (↔)
CYP2C9 (Y)
CYP3A4 (Y)
CYP2C19 (↔)
CYP2D6 ([)

No clinically
The metabolic
signiﬁcant
GMR (90% CI):
xrelevant
(1) 0.870
(0.805e0.940) for
caffeine to paraxanthine (CYP1A2)
(2) 0.871 (0.800

Ref

[157]

[158]

[159]

[160]
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Ginseng
(Panax
ginseng)

Warfarin
SD rats,
0.2 mg/kg, po, 5 days n ¼ 6 in
each group

Ingredient
mentioned

fexofenadine 30 mg,
po, single dose

Human healthy
subjects,
sequential
n ¼ 15

C54BL/6N
Cocktail probe:
mice, n ¼ 3
caffeine 2
mg/kg,
bupropion 30
mg/kg, omeprazole
4 mg/kg,
dextromethorphan
40 mg/kg, midazolam 2 mg/kg, po,
single dose

RGE (dried
Ginseng >60%,
Ginsenosides
85.1 mg/d), po,
qd, 15 days

Korea RGE from
0.5 e 2.0 g/kg/d,
po, 2 or 4 weeks

RG does
[161]
not cause clinically
relevant HDI

NA

[162]
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Cocktail probe:
caffeine 100 mg,
losartan 50 mg,
omeprazole 20 mg,
dextromethorphan
30 mg, midazolam
2 mg, and atorvastatin 2 mg, po, single
dose

e0.947) for losartan
to EXP3174
(CYP2C9)
(3) 1.027 (0.938
e1.123) for omeprazole to
5-OH omeprazole
(CYP2C19)
(4) 1.373 (0.864
e2.180) for dextromethorphan to
dextrorphan
(CYP2D6)
(5) 0.824 (0.658e
1.032) for midazolam to 1-OH
midazolam
(CYP3A4)
Ginsenosides Rb1, Rb2, CYP1A2 (Y) OATP1B1 (↔) The GMR of
Rc, Rd, Re, Rg1, Rg3,
CYP2C19 (Y)
metabolite
and Rh1
CYP2D6 (Y)
AUC (90% CI)
CYP2C9 (↔)
for the probe drugs:
CYP3A4 (↔)
(1) within 0.8e1.25
(CYP2C9, CYP3A4,
and OATP1B1
probe substrates)
(2) within 1.25e2
(CYP1A2,
CYP2C19, and
CYP2D6 probe
substrates)
NA
The metabolic
Ginsenosides Rb1, Rb2, CYP3A ([)
GMR of 4 weeks
Rc, Rd, Re, Rf, Rg1, Rg3, CYP2D (Y)
Rh1, Rh2, F1, F2, ComRGE administrapound K, prototion:
panaxadiol, and
(1) RGE 0.5 g/kg:
protopanaxatriol
Midazolam ([)
51.2%
(2) RGE 1 g/kg:
Midazolam ([)
57.8%
Dextromethorph
(Y) 29.9%
(3) RGE 2 g/kg:
Midazolam ([)
68.3%
compound
O, compound Y, Protopanaxadiol, and
Protopanaxatriol
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TCM
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CVD Drug

Study
design

TCM
administration
(dose, route,
duration)

Ingredient
mentioned

Possible
underlying mechanism
Phase I & II

Transporter

Signiﬁcant
Physiological
effect on PK
impact
of concurrent druga
Dextromethorph
(Y) 53.6%
No signiﬁcant
changes

Ref

SD rats, n ¼ 4e7 RG from 0.5 to
2 g/kg/d, po,
2 weeks

Ginsenosides Rg1 and
Rb1

CYP3A4 (↔)
CYP2C9 (↔)

NA

Human healthy Ginseng 200
subjects, n ¼ 22 mg/d, 18 days
SD rats, n ¼ 4 (1) RGE 1.5 g/kg/d,
po, 7 days
(2) Rc 3 mg/kg/d,
iv, 5 days

NA

CYP3A4 (Y)

NA

Cmax ([) 53.4%

Oatps (↔)

PK:
Warfarin 1 mg/kg,
po, single dose
PD:
Warfarin 0.4
mg/kg, po,
7 days
alone þ 3 weeks
GS coadministration
(1) Warfarin 2
mg/kg, po, single
dose
(2) Warfarin
0.2 mg/kg/d, po,
6 days
Warfarin 0.25
e0.32 mg/kg,
po, 7 days

SD rats, n ¼ 10 PK:
in each group
Ginsenosides
300 mg/kg/d,
po, 3 weeks
pretreated
PD:
Ginsenosides
30, 100, and 300
mg/kg/d, po,
3 weeks
SD rats, n ¼ 6 in Ginseng crude
each group
drug, 2 g/kg,
po, bid, 5 days

Ginsenosides Rg1, Re,
Rd, Rf, Rb1, Rb2, Rc,

CYP3A ([)
CYP2C ([)

NA

May be due to high NA
[164]
protein binding
and limited liver
distribution of GS,
no effect on valsartan PK
AUC (Y) 45.5%
(1) The expression [99]
CL/F ([) 84.0%
of factors II, VII
and protein Z
elevated
(2) Repeated GS
signiﬁcantly
decrease the INR

NA

NA

NA

No signiﬁcant
changes in PK
parameters

No signiﬁcant
change in PT

Hyperlipidemia Ginsenosides
rats, n ¼ 5 in
from 50,
each group
100, and 200
mg/kg/d, po,
1, 2, and 3 weeks
Human
P. ginseng
ischemic stroke aqueous extracts,
patients, open- 0.5 g, po, tid,
label n ¼ 12 & 13 2 weeks

Ginsenosides Rg1, Re,
Rb1 and Rd

CYP1A ([)
CYP2C ([)
CYP3A ([)

NA

No PK studies
mentioned

NA

NA

NA

No PK studies
mentioned

The expression of [165]
factors II, VII and
protein Z elevated.
Repeated GS could
decrease the INR
No statistically dif- [166]
ference in PTmax,
AUCPT, INRmax,
and AUCINR

Warfarin 2 mg
in ﬁrst week and
5 mg in second
week, po

NA

[163]

NA

[101]

[100]

b
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(1) Losartan 10
mg/kg, po, single
dose
(2) Losartan
10 mg/kg, iv,
single dose
Nifedipine, 10 mg,
po
Valsartan 1 mg/kg,
iv, single dose

Ginsenosides Rb1, Rb2, NA
Rc, Rd, Rg3, compound
K, and Rh2
(protopanaxadiol
type, PPD-type)
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Table 3. (continued )

Warfarin 25
mg, po, single dose

Warfarin 40.6
mg/week (in
average), po,
17.1 years
(in average)
Atorvastatin
1 mg/kg, po,
single dose
Atorvastatin
40 mg, po,
single dose

Human healthy GBE 360 mg/d,
subjects,
po, 14 days
sequential
n ¼ 16

Amlodipine
1 mg/kg, po,
single dose

SD rats, n ¼ 6 in GLT 100 mg/kg/d,
each group
po, 10 days

Cilostazol
100 mg, po

Human,
GBE, 80 mg, po,
healthy
q12h, 7 days
Korean subjects,
n ¼ 34

Cilostazol 100
mg þ
Clopidogrel 75
mg, po

Human,
G. biloba, 120 mg,
healthy
single dose, po
subjects, n ¼ 10

Ginsenosides Rg1 and
Rb1

CYP1A2 (↔)
CYP3A4 (↔)
CYP2C9 (↔)

NA

No signiﬁcant
changes

No signiﬁcant
[167]
change in INR and
platelet
aggregation.

Ginsenosides
Rg3, Rh2, and Rf

NA

NA

No PK studies
mentioned

No signiﬁcant dif- [168]
ferences in
mean INR change
but have a
tendency

Ginkgolide A,
ginkgolide B,
bilobalide, quercetin,
and kaempferol
Ginkgolides
A, B, C, J,
bilobalide,
quercetin,
kaempferol, and
isorhamnetin
Ginkgolides A, B,
and C, bilobalide,
quercetin, kaempferol,
and isorhamnetin
NA

CYP3A (Y)

NA

Cmax ([) 32.1%
AUCt ([) 75.8%
t1/2 ([) 26.7%

NA

[169]

CYP3A4 (↔) OATP1B1 ([)
UGT1A1 (↔)
UGT1A3 (↔)

Cmax (Y) 28.9%
AUCt (Y) 14.3%
CL/F ([) 6.5%

No signiﬁcant
change in
cholesterollowering
efﬁcacy

[125]

CYP3A (Y)

NA

Cmax ([) 39.0%
AUC ([) 79.3%
t1/2 ([) 67.6%

NA

[170]

CYP3A4 (↔)
CYP1A2 (↔)
CYP2E1 (↔)
CYP2D6 (↔)

NA

No signiﬁcant
changes

NA

NA

NA

[171]
No signiﬁcant
changes in
bleeding times
and adverse drug
reactions
between the
treatments
[172]
Potentiated the
bleeding time
prolongation
effect of
cilostazol, but
no signiﬁcant
change in antiplatelet
activity, bleeding
time, clotting time
and platelet count

NA
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Ginkgo
(Ginkgo
biloba)

Human healthy Ginseng cap,
subjects, cross- 2's (each capsule
over n ¼ 12
containing
GBE equivalent to
0.5 g P. ginseng root
and 8.93 mg GS Rg1),
po, tid, 1 week
Human cardiac RGE, 1 g, po,
6 weeks
valve
replacement
patients,
cross-over
n ¼ 25
SD rats, n ¼
GLT, 80 mg/kg/d,
6 in each group po, 10 days

(continued on next page)
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TCM

Study
design

TCM
administration
(dose, route,
duration)

Ingredient
mentioned

Possible
underlying mechanism
Phase I & II

SD rats, n ¼ 7 in GBE, 4, 20,
each group
and 100 mg/kg/d,
po, 14 days
pretreated

Ginkgolides and
bilobalide

Digoxin
0.1 mg/kg,
po, single dose

SD rats, n ¼
6 in each
group

GBE 160 mg/kg,
po, single dose

Losartan
10 mg/kg, po,
single dose

SD rats,
n ¼ 6 in
each group

GLT 80 mg/kg/d,
po, 10 days

Ginkgolides A, B,
NA
and C, bilobalide,
quercetin, kaempferol,
and isorhamnetin
Ginkgolides A, B,
CYP3A (Y)
bilobalide, quercetin
CYP2C (Y)
and kaempferol

High dose:
Low dose:
CYP1A2 ([) P-gp (Y)
CYP2C19 ([)
CYP2D6 (Y)
Medium
dose:
CYP2C19 ([)
CYP3A4 ([)
CYP2B6 ([)
CYP2C9 ([)
CYP2A1 ([)
High dose:
CYP1A2 (Y)
CYP2C19 (Y)
CYP2D6 ([)

P-gp (Y)

NA

pretreated

Pitavastatin
0.135 mg/kg,
po, single dose

NAFLD rats,
n ¼ 6 in
each group

GBE 3.6, 10.8,
and 32.4 mg/kg/d,
po 2 or 4
weeks pretreated

Ginkgolides A, B, C,
bilobalide, quercetin,
kaempferol, and
isorhamnetin

NA

Oatp1b2 (Y)

Ref

(1) Clopidogrel
NA
GBE 4 mg/kg/d:
Cmax (Y) 38.5%
CL/F ([) 64.1%
GBE 20 mg/kg/d:
Cmax (Y) 56.3%
AUC∞ (Y) 46.2%
CL/F ([) 96.1%
GBE 100 mg/kg/d:
Cmax (Y) 87.5%
AUC∞ (Y) 69.2%
CL/F ([) 264.1%
(2) Clopidogrel
active metabolite
GBE 100 mg/kg/d:
Cmax ([) 120.5%
AUC∞ ([) 140.1%
CL/F (Y) 59.0%
Cmax ([) 25.4%
NA
AUCt ([) 27.8%

[173]

NA
(1) Losartan:
Cmax ([) 51.6%
AUCt ([) 70.8%
CL/F ([) 42.7%
(2) EXP3174:
Cmax (Y) 31.4%
AUCt ([) 44.5%
CL/F ([) 72.0%
NA
(1) 2-weeks pretreated
GBE 10.8 mg/kg/d:
Cmax ([) 155.9%
GBE 32.4 mg/kg/d:
Cmax ([) 210.8%
AUCt ([) 129.6%
(2) 4-weeks pretreated
GBE 3.6 mg/kg/d:
CL/F (Y) 41.1%
GBE 10.8 mg/kg/d:
Cmax ([) 163.5%
AUCt ([) 135.2%
CL/F (Y) 57.2%
GBE 32.4 mg/kg/d:
Cmax ([) 219.0%
AUCt ([) 199.3%
CL/F (Y) 58.9%

[174]

[175]

[126]
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Clopidogrel 7.5
mg/kg, po, single
dose

Transporter

Signiﬁcant
Physiological
effect on PK
impact
of concurrent druga
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Interacted
CVD Drug

Simvastatin:
Cmax (Y) 32%
AUC∞ (Y) 36%
No signiﬁcant
differences in
simvastatin acid
PK
Single dose GBE:
No effect on
talinolol PK
Repeated GBE:
Cmax ([) 36.3%
AUCt ([) 26.2%
No signiﬁcant
changes

No signiﬁcant PD [124]
change of simvastatin but trended
towards lowering
LDL-C efﬁcacy
(p ¼ 0.056)

Quercetin, kaempferol, Effect on simapigenin, ginkgolides vastatin:
A, B, C, J and M, and CYP3A ([)
bilobalide

Effect on simvastatin:
P-gp ([)
Effect on simvastatin acid:
OATP1B1 (Y)

Talinolol
100 mg, po, single
dose

GBE tab, 120 mg,
po, tid, 14 days

NA

NA

P-gp (Y)

GBE 80 mg, po,
single dose

Glycosidic
ﬂavonoids 24% and
terpenoids 6% of GBE

NA

NA

GBE from 10 &
100 mg/kg/d,
po, 5 days

Bilobalide

CYP1A1 ([)
CYP1A2 ([)
CYP2B ([)
CYP2C ([)
CYP3A ([)
CYP1A2 (↔)
CYP3A4 (↔)
CYP2C9 (↔)

NA

GBE 100 mg/kg:
(R)-Warfarin
Cmax (Y) 49.2%

NA

No signiﬁcant
changes in the
PK parameters

NA

CYP2C (Y)
in vitro

NA

AUC [ (15e31%)
CL Y (14e27%)

NA

[131]

Ophiopogonanone A
Ginsenoside Rd

CYP3A (Y)
in vitro

NA

AUC [ (22e33%)
t1/2 [ (22e76%)
CL Y (19e29%)

NA

[131]
[132]

SMI, 5 mL/kg,
ip, single or once
daily, 7 days

NA

NA

NA

AUC (↔)
t1/2 (↔)
CL (↔)

NA

[131]

SMS 0.95 g/kg,
po, 1 h

Schisandrin B

CYP3A (Y)

NA

Cmax [52%

NA

[133]

SMS 1.9 g/kg,
po, 1 h

Schisandrin B

hepatic
NA
CYP3A activity (Y)

CL/F (Y) 34%
t1/2 ([) 142%

NA

[133]

Ticlopidine
250 mg, po, single
dose

Warfarin
1.5 mg/kg/d for
racemate (1:1), po,
last 3 days of GBE
administered
Warfarin
25 mg, po

Human
healthy
Chinese
subjects,
sequential
n ¼ 10
Human,
healthy
Korean
subjects, crossover n ¼ 24
ICR mice,
n ¼ 4e6

Human, n ¼ 12 G. biloba tab, 2's
(each tablet is
equivalent to 2 g
of G. biloba leaf,
9.6 mg of Ginkgo
ﬂavon glycosides,
2.4 mg of
ginkgolides and
bilobalide), po,
tid, 7 days
SD rat, n ¼ 8
SMI, 5 mL/kg, ip,
single or once
daily, 7 days
SD rat, n ¼ 8
SMI, 5 mL/kg,
ip, single or
once daily, 7 days

Shenmai in- Diclofenac
0.8 mg/kg, iv
jection
(SMI)
Midazolam
1 and 4 mg/kg,
iv, 0.5 h after the
last herbal treatment
Theophylline
SD rat, n ¼ 8
1 mg/kg, iv,
0.5 h after the last
herbal treatment
ShengmaiNifedipine 3 mg/kg, SD rat, n ¼ 6
San (SMS) po
(Shengmai-Yin)
Nifedipine 3 mg/kg, SD rat, n ¼ 6
po

Ginkgolides and
bilobalide

NA

[176]

No effects

[177]

No inﬂuence on
[178]
blood coagulation
but attenuates the
anticoagulation action of warfarin
No signiﬁcant
[179]
change in INR and
platelet
aggregation

(continued on next page)
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GBE 120 mg, po, bid,
14 days

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:331e356

Simvastatin
Human,
40 mg/d, po, 14 days healthy
subjects,
n ¼ 14

REVIEW ARTICLE
Table 3. (continued )
Interacted
CVD Drug

Study
design

Nifedipine 3 mg/kg, SD rat, n ¼ 6
po

TCM
administration
(dose, route,
duration)

Ingredient
mentioned

SMS 1.9 g/kg,
po, 3 weeks

Schisandrin B
Schisantherin A
Methylophiopogonanone A
Coumarins

Possible
underlying mechanism
Phase I & II

Transporter

Cmax ([) 101%
AUCt ([) 73%
CL/F (Y) 39%

NA

NA

NA

CYP2C (Y)

NA

rat hepatic
CYP1A ([)

NA

Cmax ([) 135%
AUC ([) 208e
215%
CL/F (Y) 61%
AUCuc (Y) 71%
t1/2 (Y) 63%
CLuc ([) 244%

Enhance warfarin- [141]
prolonged PT 24 h
after warfarin
administration
NA
[180]

Rutaecarpine

rat hepatic
CYP1A ([)

NA

AUCu (Y) 73%
t1/2 (Y) 79%e85%
CLu ([) 269e259%
AUC (Y) 44%
t1/2 (Y) 39%
CL ([) 78%
AUCu (Y) 44%
t1/2 (Y) 21%
CLu ([) 93%
AUCu (Y) 26e60%
CLu ([) 35e146%

NA

[181]
[182]

NA

[144]
[183]

NA

[180]

NA

[182]

1e2 mg/kg/day,
po, 1e2 weeks

SD rat, n ¼ 4

Wu-chu-yu Caffeine
(Evodia
5 mg/kg, iv
rutaecarpa)

SD rat, n ¼ 6

1 g/kg, po,
2 h after
warfarin
administration
1 g/kg
ethanolic
extract, po,
3 days
1 and 2 g/kg
ethanolic extract,
po, 3 days
5 g/kg decoction,
po, 3 days

Angelicin
Hesperetin
Naringenin
Tetradrine
Rutaecarpine

Rutaecarpine

mouse hepat- NA
ic CYP1A ([)

SD rat, n ¼ 6

1 g/kg decoction,
po, 3 days

Rutaecarpine

rat hepatic
CYP1A ([)

NA

SD rat, n ¼ 6

1 and 5 g/kg
decoction, po, 3
days

Rutaecarpine

rat hepatic
CYP1A ([)

NA

Wu-Chu-Yu- Caffeine
Tang
2 mg/kg, ip
(WCYT)
Caffeine
5 mg/kg, iv
Theophylline
2 mg/kg, iv

C57BL/6Jmice,
n¼6

[134]
Increased headache incidence and [135]
decreased all-cause
mortality
Enhance warfarin- [140]
prolonged PT

The number of animals (n) shown in the study design was the number of animals in the treated group in the PK/PD study of herbal extracts or formula. AUC, area under curve; BA,
bioavailability; CL: clearance; DEAE, Danshen ethyl acetate extract; DDP, Danshen dripping pills; EXP3174, active metabolite of losartan; GBE, Ginkgo biloba extract (from leaves, fruit,
or both); GLT, Ginkgo leaf tablet; GMR, geometric mean ratio; INR, international normalized ratio; IPA, inhibition of platelet aggregation; NA, not available; NAFLD, non-alcoholic
fatty liver disease; PD, pharmacodynamic; PT, prothrombin time; PK, pharmacokinetic; RG, red Ginseng; RGE, red Ginseng extract; SD rat, Sprague-Dawley rat; t1/2, half-life; ([),
signiﬁcantly increase; (Y), signiﬁcantly decrease; (↔), no signiﬁcant change.
a
The alterations of PK parameters were calculated by mean differences compared to the control group in the study.
b
Conference abstract.
c
The AUC or CL of unbound drug determined in the microdialysis experiment.
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Rabbit, n ¼ 6

SD rat, n ¼ 6

Ref

NA
intestinal
CYP3A activity (Y)

Shu-JingWarfarin
1.5 mg/kg, po
HwoShiee-Tang
(SJHST)
Warfarin 1
mg/kg, po

Theophylline
2 mg/kg, iv

Signiﬁcant
Physiological
effect on PK
impact
of concurrent druga
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TCM

the complexity of the components in TCM, some of
the active ingredients may show strong inhibitory
effects on drug-metabolizing enzymes or transporters instantly after systemic exposure, but other
pharmacologically active components may exert
their transcriptionally or translationally inductive
effects after long-term administration. For example,
the hydrophobic Danshen ingredient tanshinone
IIA inhibited CYP1A activity in HLMs (inhibitor
concentration
for
causing
50%
inhibition
(IC50) ¼ 0.2e0.4 mM) [86] but induced CYP1A with
aryl hydrocarbon receptor sensitivity after repeated
treatments in mice [87]. On the other hand, tanshinone IIA had no effect on CYP2C activity in
HLMs in vitro [86] and in mice after repeated treatments [87]. Consistently, repeated treatments with
Fufan Danshen (Compound Danshen) dripping pill
did not cause signiﬁcant changes in warfarin PKs
and warfarin-prolonged prothrombin time (PT) in
rats [88] and possibly in patients with various SNPs
[89]. Treatment time is not the only determining
factor for the drug interactions with Danshen-containing prescription. The CYP selectivity of modulation, composition of Danshen extract, intake dose
and achieved plasma levels of ingredients, and
particularly the multiple metabolic pathways of
victim drugs could be crucial in determining the
dominant mechanism(s) involved in the interactions
of CVD drugs with Danshen [90]. The controversial
interaction between Danshen and prescribed drugs
is not an isolated case and can be observed in many
other TCMs that are concurrently administered,
such as Schisandra, which is discussed in the
following section of formula.
Danshen not only modulates CYPs to cause HDIs
[79e87], but it also inhibits UGTs [90,91] and
transporters [75,92]. Compared to the HDIs resulting from CYP modulation, there are relatively few
reports regarding UGT/transporters-mediated interactions. A noteworthy clinical case associated
with the induction of P-gp by Danshen has been
published [72]. The systemic exposure (AUC) to the
P-gp
substrate,
fexofenadine,
signiﬁcantly
decreased by 37% after repeated treatments with
Danshen ethanolic extract. To further conﬁrm
transporter/UGT-mediated HDIs with Danshen,
more in vivo studies are warranted to evaluate the
interactions between Danshen-containing formulas
and CVD drugs.
3.2. Ginseng (P. ginseng)
P. ginseng, cultivated for its rhizomes (Ginseng
Radix), is a medicinal plant belonging to the Araliaceae family. As a valued healthcare product,
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Ginseng has enjoyed a reputation for thousands of
years and is now becoming increasingly popular
worldwide [93,94]. The constituents of Ginseng [95],
including ginsenosides, ﬂavonoids, sterols, and polysaccharides (Table 2), have been shown to possess
anti-fatigue, anti-hypertensive, immunomodulatory,
anticancer, and antidiabetic properties, as well as to
alleviate numerous other maladies. Thus, Ginseng is
used as an adjuvant to a variety of compound TCMs,
owing to its versatile disease treatments. Due to its
low toxicity and safety for general consumption [96],
patients could use Ginseng as a complementary
medicine and even self-medicate without notifying
their physicians. However, more than 40 ginsenosides
belonging to a group of steroidal saponins are active
components in Ginseng and may cause clinical HDIs
[93,96,97].
According to Chinese medical practice, distinctly
processed Ginseng should be used in patients with
different symptoms of health status. Ginseng can be
used in Chinese medical care for the treatment of
myocardial infarction, angina pectoris, and congestive heart failure [98], making it highly suitable in
combination with CVD drugs [94]. Reports of
Ginseng-drug interactions are highly contradictory,
and the causality remains uncertain due to variations in dosing regimens and experimental designs
among studies [93]. However, a few reports have
indicated that potential HDIs exist with the concurrent use of blood circulation aids or drugs primarily metabolized by CYP3A4 [99,100]. Most of the
reports revealing signiﬁcant Ginseng-drug interactions are based on in vitro ﬁndings, such as
those involving hepatocytes, supersomes, and microsomes [93]. Direct exposure to the incubation
matrix may exaggerate the modulatory strength of
ginsenosides on metabolic enzymes or transporters
owing to the lack of complete PK behavior and
leading to inconsistent results in in vivo and in vitro
studies. To our knowledge, only two clinical trials
have shown signiﬁcant Ginseng-drug interactions,
which have the potential to be clinically relevant.
However, these two studies revealed contradictory
results regarding the changes in plasma levels of the
CYP3A4 substrates, nifedipine and midazolam
[101,102]. With the concurrent use of warfarin,
several clinical observations have indicated that
Ginseng products might increase the risk of
bleeding [103,104]. A more recent case report
demonstrated that Ginseng may indirectly result in
liver injury and myositis in a patient consecutively
treated with atorvastatin, potentially through
Ginseng-mediated inhibition of CYP3A4 or
OATP1B1 [105]. Although the reported interactions
between Ginseng and co-administered Western
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drugs are conﬂicting and most of them have been
deemed clinically inconsequential, it is still recommended to closely monitor the plasma levels of
CVD drugs with narrow therapeutic indices or
heavy
dependence
on
CYP3A4-mediated
metabolism.
To date, the underlying mechanisms of Ginsengrelated HDIs are primarily mediated by CYPs.
Recent research on Ginseng-drug interactions has
been extended to include transporters or UGTs
[106e109]. Because some of deglycosylated ginsenosides are believed to be more active in interfering
with the metabolism of co-therapeutic drugs
[110,111], active metabolites produced by the gut
microbiota are thought to be more likely to affect
UGTs and transporters, especially in enterocytes
[93]. In addition, it is worth noting that the inconsistencies in Ginseng-drug interactions between
in vitro and in vivo results or between laboratory
studies may be caused by many uncontrolled variables, such as dosing regimens, TCM cultivation
conditions, and matrix differences. The dosedependent biphasic effects of Ginseng may also be
one of the reasons for the contradictory results [112].
3.3. Ginkgo (G. biloba)
The seeds of G. biloba (Ginkgo Semen) have been
used as an herbal medicine in the Chinese Material
Medica. The leaves of G. biloba (Ginkgo Folium) are
now utilized globally, especially in Western countries. G. biloba is mainly used to improve cerebrovascular or peripheral vascular diseases and is
frequently used to enhance cognition in the central
nervous system [113,114]. G. biloba leaf extract (GBE)
is a primary product (e.g., EGb 761) that is currently
used in disease treatment or as a dietary supplement. Long-term use can promote peripheral blood
circulation, improve the elasticity of blood vessels,
lower blood lipids, and exhibit a myocardial protective effect [96,114]. The therapeutic effects of GBE
on CVD are suggested to be mainly due to its two
major types of active ingredients: ﬂavonoids and
terpene trilactones (Table 2). Published reports
indicate that GBE mainly exerts antioxidant and
anti-inﬂammatory effects through these two active
ingredients, thereby protecting cardiovascular
function [96].
Similar to Danshen, although there is more evidence regarding potential HDIs, the contraindications between Ginkgo and prescribed drugs remain
highly uncertain [114]. Flavonoids have been shown
to regulate the function of drug-metabolizing enzymes and transporters, and extensive research in
this area has been reported [115,116]. Since one of

the biological functions of Ginkgo itself is to
improve blood circulation, it is common for patients
to take GBE as a complementary medicine in the
course of CVD treatment, especially concurrent with
antithrombotic or antiplatelet drugs. Therefore, the
most frequent case reports still involve drug interactions related to bleeding after the combined
use of G. biloba [117e119]. Although a variety of in
vitro results have indicated that GBE signiﬁcantly
decreased the oxidation activities toward CYP substrates [120,121], the results of clinical studies did
not support the hypothesis that GBE can affect CYP
activity in humans [121,122]. However, since there is
a high possibility that GBE and anticoagulant or
antiplatelet drugs could be co-administered, the risk
of bleeding should be considered, particularly when
they are concurrently used in long-term treatment
[123].
In addition to drug substrates of CYPs, numerous
studies have shown that G. biloba signiﬁcantly alters
the PK properties of statins by modulating transporter function [124e126]. The capability of GBE on
the modulation of P-gp remains controversial (Table
3); however, more evidence suggested that OATP1B
members could be the target transporters modulated by the active ingredients of G. biloba [124e127].
More detailed studies (such as PXR and gut microbiota) related to the underlying mechanism of
transporter changes by G. biloba are currently in
progress [126,128].

4. Potential HDIs between TCM formulas and
prescribed CVD drugs
4.1. Shenmai injection (SMI) and Shengmai San
(SMS) (Shenmai-Yin)
SMI is derived from the traditional Chinese herbal
prescription Shendong yin, which consists of
Ginseng and Ophiopogonis Radix (the tuber of
Ophiopogon japonicus) [130]. In China, SMI has been
widely used for the treatment of chronic heart failure. Both acute (0.5 h) and 7-day intraperitoneal
treatment of rats with SMI (5 mL/kg) increased the
AUC and decreased the clearance of midazolam (a
CYP3A substrate), suggesting a potential PK interaction with CYP3A drug substrates [131,132]. Since
midazolam was administered 0.5 h after SMI in both
treatments, acute effects were included in the
changes after repeated treatments. However, PKs of
theophylline remained unchanged under the SMI
treatment, suggesting the lack of inﬂuence on the
metabolism of CYP1A2 drug substrates.
Different from the administration method and
component herbs of SMI, SMS is administered

orally and contains an additional TCM, Schisandrae
Fructus (the ripened fruit of Schisandra chinensis). In
Taiwan's TCM prescriptions for patients with
ischemic heart disease, 16% of prescriptions contained SMS, which was among the top three
frequently used formulas [78]. A 1-h pretreatment of
rats with SMS decreased nifedipine clearance,
accompanied by decreased hepatic oxidation activity, which was primarily catalyzed by CYP3A [133].
However, 3-week repeated oral treatments with
SMS suppressed rat intestinal, but not hepatic,
nifedipine oxidation activity [134]. Accordingly,
nifedipine clearance decreased and AUCt increased.
In patients taking nifedipine/felodipine, additional
SMS treatment increased the incidence of headaches but decreased all-cause mortality [135].
The decreased CYP3A activity can be attributed, at
least in part, to the Ophiopogonis Radix-mediated
suppression of intestinal CYP3A activity. The results
of the in vitro inhibition study indicated the presence
of time-dependent CYP3A inhibitor(s) in SMS.
Among the SMS ingredients, the Schisandra lignan,
schisandrin B was reported to be a PXR activator
[136] but also potently inhibited rat liver microsomal
CYP3A activity [133]. Although drug interactions
occur in vivo, reversible and irreversible inhibition,
as well as induction, may work in a complex
manner. At an equivalent dose to that from Schisandrae Fructus in SMS preparations, Schisandrae
Fructus decoction (0.35 g/kg/day, 3 weeks) could not
stimulate nifedipine oxidation activity [134]. These
reports suggest a potential dose-dependent mixed
type of CYP3A modulation by Schisandra ingredients. Thus, in addition to the impaired intestinal CYP3A function by Ophiopogonis Radix and
its ingredients, the potent inhibition of nifedipine
oxidation by schisandrin B/schisantherin A should
be considered during repeated SMS treatments
[134,135].
Methylophiopogonanone A, an active homoisoﬂavonoid of Ophiopogonis Radix, has been reported to strongly inhibit UGT1A1 (IC50 ¼ 1.23 mM)
and several other UGT isozymes (IC50 < 8.30 mM)
in HLMs [137]. Six Schisandra lignans in S. chinensis have mild-to-moderate inhibitory effects on
UGT1A1 and UGT1A3 activities (IC50 > 15 mM) in
HLMs [138]. Deoxyschizandrin and schisantherin
A inhibit UGT1A3 with IC50 values equal to 10.8
and 12.5 mM in a recombinant UGT system,
respectively [139]. However, acute (1 h) and
repeated (daily for 3 weeks) treatments with SMS
powdered decoction did not cause signiﬁcant
changes in rat hepatic and intestinal UGT activities
[133,134]. To reveal the impact of UGT inhibition
by these ingredients of SMS component herbs,
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further studies on the PK changes in glucuronide
metabolites are crucial.
4.2. Shu-Jing-Hwo-Shiee-Tang (SJHST)
SJHST is an herbal formula prepared using 17
herbs, namely Paeoniae Radix (Paeonia lactiﬂora),
Angelica sinensis Radix (Danggui, A. sinensis),
Rehmanniae Radix (Rehmannia glutinosa), Persicae
Semen (Prunus persica), Cyathulae Radix (Chuan Niu
Xi, Cyathula ofﬁcinalis), Citri Reticulatae (Citrus
reticulate), Clematidis Radix (Clematis chinensis),
Atractylodis Rhizoma (Atractylodes lancea), Gentianae Radix et Rhizoma (Gentiana scabra), Poria (Poria
cocos), Chuanxiong Rhizoma (Ligusticum chuanxiong),
Stephaniae tetrandrae Radix (Stephania tetrandra),
Notopterygii Rhizoma et Radix (Notopterygium incisum), Saposhnikoviae Radix et Rhizoma (Saposhnikovia divariata), Angelicae dahuricae Radix (Bai
Zhi, Angelica dahurica), Zingiberis Rhizoma (Ginger,
Zingiber ofﬁcinale) and Glycyrrhizae Radix et Rhizoma (Gan cao, licorice, Glycyrrhiza uralensis) [140].
In patients with hypertension, the frequency of
SJHST use in prescriptions was 4.5% in Taiwan [7].
SJHST has been frequently used in patients with
thrombosis-associated pain and osteoarthritis, and
prolonged PT has been observed in patients
receiving both SJHST and warfarin treatments for
1e2 weeks [140]. A 2-week SJHST treatment did not
affect coagulation parameters in rabbits. However,
compared to rabbits treated with warfarin alone, the
coagulation parameters PT and activated partial
thromboplastin time (APTT) were signiﬁcantly
prolonged in the rabbit group concurrently and
repeatedly treated with SJHST (1e2 mg/kg/day) and
warfarin (1.5 mg/kg/day) for 2 weeks [140] (Table 3).
In a rat study, co-treatment with SJHST (1 g/kg) and
warfarin did not alter the PKs of warfarin [141].
However, SJHST administration to rats 2 h after
warfarin treatment resulted in 2e3-fold increases in
the Cmax and AUC of warfarin. Consistent with the
increased AUC, PT was prolonged 24 h after
warfarin administration when SJHST was administered 2 h after warfarin. Alterations in the PK parameters of warfarin may be one of the factors
leading to the increase in coagulation time by SJHST
in the warfarin-treated group. In addition, there was
no signiﬁcant change in plasma warfarin level when
SJHST-enhanced PT elongation was detected 24 h
after warfarin treatment. At 8 h, with a maximal
increase in plasma warfarin levels, PT remained
unchanged. The lag time required for pharmacological changes in the victim drug should be
considered in the HDI assessment. These animal
studies suggest that an appropriate time interval
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between the administration of SJHST and the drugs
should be considered to prevent adverse effects in
patients receiving both treatments.
The extracts of some component herbs of SJHST
showed potential antiplatelet aggregation and PK
interactions with warfarin. Platelet aggregation
decreased when ginger was administered at a high
daily dose of 5 g, but not at 3.6 g, in healthy volunteers [142]. Indeed, SJHST (at a dose equivalent to
the human daily dose of SJHST prepared from the
decoction containing 3 g ginger) alone did not affect
PT in rats. In rabbits, the aqueous extract of A.
sinensis Radix (2 g/kg) has been reported to reduce
PT without affecting the PKs of a single dose of
warfarin (subcutaneous). In rats, the aqueous extract
of Chuanxiong Rhizoma (10 g/kg) increased the
AUCt of warfarin (oral) [143], but Glycyrrhizae
Radix et Rhizoma extract (0.9 g/kg) increased
warfarin (intravenous) clearance [136]. The SJHSTmediated increase in the AUC of plasma warfarin
can be associated with decreased 7-hydroxylation of
warfarin, which is the primary metabolic pathway of
pharmacologically active S-warfarin. This inhibition
did not show the characteristics of a time-dependent
CYP inhibitor [141]. Among the digested ingredients
of component herbs, angelicin, hesperetin, naringenin and tetrandrine inhibit warfarin 7-hydroxylation [141]. These ingredients may contribute to
the decreased elimination of warfarin after SJHST
consumption.
4.3. Wu-Chu-Yu-Tang (WCYT) or Wu-Zhu-YuTang
WCYT (Goshuyu-to in Japanese Kampo medicine) contains Evodiae Fructus (Wu-Chu-Yu or WuZhu-Yu, Evodia rutaecarpa), Ginseng Radix (ginseng,
P. ginseng), Zingiber Rhizoma (ginger, Z. ofﬁcinale),
and Zizyphi Fructus (Tai-Geui, Ziziphus jujuba).
WCYT is used for the treatment of migraine and
vomiting accompanied by a cold and heart failure
[144,145]. WCYT has been reported to retain body
temperature in chlorpromazine-treated rats and
inhibit platelet aggregation in whole blood from
guinea pigs [146,147]. Repeated treatment with
WCYT decoction potently stimulates CYP1A activity
and the expression of CYP1A2 in mice [144]. Among
the component herbs of WCYT, Evodiae Fructus
and its main alkaloids rutaecarpine contribute to
CYP1A induction [144]. Consistent with CYP1A2
induction, oral administration of WCYT to mice or
rats increased the clearance of CYP1A2 substrates
caffeine and theophylline (Table 3). A 3-day oral
treatment with the alkaloid rutaecarpine (25e80 mg/
kg) resulted in 26e95% decreases in the AUCs of

acetaminophen (intravenous), caffeine (oral), and
theophylline (intravenous) [144,146,148]. Reports
showing only the determination of mRNA levels
and in vitro studies without corroborating in vivo
effects are not discussed here. Further human
studies are crucial to examine the therapeutic efﬁcacy of CYP1A2 drug substrates in patients
receiving TCMs containing Evodiae Fructus.

5. Summary and perspectives
This review collected updated evidence that
multiple factors shown in Fig. 3 should be noted in
the combined use of TCMs and drugs in CVD patients. Bi-functional modulations are common in
studies on HDIs. Literature reports indicate that the
extracts of Danshen, Ginseng and Ginkgo might
have contradictory effects on drug exposure,
potentially due to (1) different source/preparation
of the herb remedies, (2) diverse mechanisms of
drug metabolism modulation, and (3) enzymetransporter interplay involved in drug absorption
and elimination. Thus, the dosing regimen (dose
and frequency), metabolism-mediated modulatory
effects (reversible or irreversible), and PK/PD
properties (absorption, distribution, metabolism,
and elimination (ADME) and onset of efﬁcacy) of
herbs and drugs are the determining factors for the
occurrence of HDIs (Fig. 3). Unlike the immediate
effect exerted by reversible inhibition, the induction of CYP/UGT/transporters requires a period of
time, and repeated treatments are generally
required for HDIs. For time-dependent CYP inhibitors, such as SMS, the time-period is also
essential for the formation and accumulation of
inactivated CYP to cause HDIs. In clinics, the PK/
PD properties of the herb/drug are important factors for HDI assessment. SJHST is a good example
of that because the enhancement of warfarin-prolonged PT occurs in the late stage of elimination
phase where no signiﬁcant changes in plasma
warfarin levels. However, it should be noted that,
despite understanding the chemical composition of
herbs, the involvement of herbal polysaccharides,
proteins, and lipids in HDIs requires further evaluation. Finally, the three single herbs and four
compound prescriptions discussed in this review
are frequently prescribed as CVD treatments and
therefore are very likely to be used in combination
with CVD drugs. HDIs are a double-edged sword.
The interactions between Chinese and Western
medicines are not entirely unfavorable. If HDIs can
be used wisely to improve the therapeutic effects of
disease treatment (e.g., by reducing the
drug dosage, prolonging the dosing interval, or
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Fig. 3. Determinants of the adverse or beneﬁcial effect in patients receiving both the herbal decoction and drug treatments. The composition and
preparation, the CYP/UGT/transporter modulatory effects and ADME (absorption, distribution, metabolism and elimination) of the herbal decoction
determine its complex effects on drug metabolism. When patients receive both herbal and drug treatments, in addition to the herb-induced complex
effects, the herb-induced PK interaction with the drug can be affected by the physiological/environmental factors of metabolic modulation, dosing
regimen of herb/drug, and ADME of the drug. Finally, the pharmacodynamics and toxicities of herb/drug should be considered to assess the beneﬁcial
and adverse effects in patients. ADME: absorption, distribution, metabolism and elimination; SNP: single nucleotide polymorphism.

diminishing the side effects), clinicians will have
one more option in their choice of treatments.
However, in the application of TCMs in patients

with CVD, particularly those who require longterm drug treatment, both the metabolic alterations
and PK/PD properties of herbs and drugs should
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be considered to weigh the advantages and disadvantages of their combination therapy.
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